Infliximab Biosimilar - Research Grade

Target: TNF alpha.

Specificity: Detects human TNF-alpha. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Infliximab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Infliximab biosimilar is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab biosimilar is produced by a recombinant cell line cultured by suspension culture and is purified by a series of steps that includes measures to inactivate and remove viruses.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.